Maxim Group Rates Zevra Therapeutics (ZVRA) buy, $35 Price Target

Analyst Jason McCarthy keeps a buy rating and a $35 target on Zevra Therapeutics, Inc., setting up a wide gap between current trading levels and expected value, a 178.88% upside from the current price.

By TradeTexts Research Desk · Published Jun 13, 2026, 2:07 AM EDT · Updated Jun 16, 2026, 9:02 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Maxim Group rated Zevra Therapeutics, Inc. ($ZVRA) "buy" with a $35 price target on June 10, 2026.

Since the rating, $ZVRA is down 6.6% after 1 week, down 1.1% after 1 month and down 26.4% to date (from the $13.50 close on Jun 10, 2026).

ZVRA Zevra Therapeutics, Inc.

$9.94 +19.18% year to date

Daily close · Oct 16, 2026

Key Points

Maxim Group analyst Jason McCarthy reiterated a buy rating on Zevra Therapeutics, Inc. (NASDAQ: ZVRA) on June 10, 2026, setting a $35.00 price target.
Maxim Group's $35 price target implies 178.88% upside from Zevra Therapeutics, Inc.'s ($ZVRA) current $12.55 share price.
Shares trade around $12.55, well below the $35 target and the overall analyst mean price target of $25.00 across nine tracked opinions.
Zevra Therapeutics reports solid fundamentals with $136.1 million in revenue and positive earnings per share of $0.93.

Get $ZVRA trade alerts by text

We text you when insiders, Congress or big funds trade $ZVRA. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Zevra Therapeutics, Inc. alert may contain errors. Disclosures

Maxim Group Analyst Reaffirms Outlook for Zevra Therapeutics Stock

Maxim Group reaffirmed its positive stance on Zevra Therapeutics, Inc. (NASDAQ: ZVRA) on June 10, 2026. Analyst Jason McCarthy kept a buy rating on the shares alongside a $35.00 price target. This target sits far above where the biotech firm changes hands in the market, drawing attention to how far Wall Street expects the shares to climb.

Where Zevra Therapeutics Stock Trades Today

The shares recently changed hands at $12.55, giving the company a market value of roughly $693.0 million. Over the past year, the stock has traded as low as $7.88 and reached a high of $15.04. The equity currently sits above both its 50-day moving average of $11.63 and its 200-day moving average of $10.45, reflecting steady upward momentum in recent months.

12-month forecast

$ZVRA price target

Zevra Therapeutics, Inc. daily closes and this analyst's $35 target. Not advice.

Broad Analyst Coverage and Price Targets

Wall Street houses maintain a strong buy consensus on Zevra Therapeutics, backed by nine analyst opinions. The overall mean price target rests at $25.00, with high estimates reaching $35.00 and low estimates touching $20.00. Other firms have recently adjusted their views to match changing market conditions. On August 20, 2026, HC Wainwright & Co. reiterated a buy rating with a $26.00 target. Guggenheim maintained a buy rating on August 7, 2026, while adjusting its target from $24.00 to $23.00. Citizens kept a market outperform rating on August 6, 2026, raising its target from $25.00 to $28.00. Earlier in the summer, Canaccord Genuity maintained a buy rating on July 27, 2026, adjusting its target from $29.00 to $20.00. On that same day, Guggenheim maintained a buy rating with a target of $24.00, down from $29.00, while BTIG kept a buy rating while lowering its target from $27.00 to $24.00. Back on June 23, 2026, HC Wainwright & Co. also kept a buy rating with a $26.00 target.

Recent Earnings and Financial Health

Zevra Therapeutics generates revenue through specialized treatments targeting rare diseases. The company posts $136.1 million in annual revenue alongside a strong revenue growth rate of 53.3%. Profitability measures show a net margin of 42.8% and a return on equity of 34.8%. Earnings per share stand at $0.93, backed by solid liquidity ratios including a current ratio of 5.17 and a quick ratio of 5.02.

What Zevra Therapeutics Does

Zevra Therapeutics is a commercial-stage biotechnology firm based in Boston, Massachusetts. The company focuses on developing and delivering therapies for rare conditions through platforms like its Ligand Activated Technology. Its portfolio includes commercial products such as AZSTARYS for attention deficit hyperactivity disorder, OLPRUVA for urea cycle disorders, and MIPLYFFA for Niemann-Pick disease type C. It also advances late-stage clinical candidates for idiopathic hypersomnia, narcolepsy, and vascular Ehlers-Danlos syndrome.

Looking Ahead for Zevra Shares

Investors keep a close watch on the company's clinical updates and financial milestones as they await the next earnings report scheduled for November 4, 2026. While analyst targets like Maxim Group's $35 figure point to significant upside, market participants continue to monitor how pipeline execution aligns with these growth projections.